Company profile
Halozyme Therapeutics, Inc.
NASDAQ: HALO · Healthcare · Biotechnology
#131 of 1,422 Healthcare companies by revenue74th-percentile growth
EA Score
85AFH 84DQ 93GM 75SS 85
v0.1 · 65/100 weight · provisional
↑ return on equity, operating margin · ↓ balance-sheet leverage, revenue growth (YoY)
Methodology →Revenue TTM
$1.5B
Rev growth YoY (TTM)
+39.1%
Net income (FY)
$316.9M
Employees
423
as of 2026-08-06
Market cap
$9.9B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.4B$1.4B2025
Net income$316.9M$316.9M2025
Operating income$469.0M$469.0M2025
Total assets$2.5B$2.5B2025
Liabilities$2.5B$2.5B2025
Equity$48.8M$48.8M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Royalty54%
Product23%
Collaborative Agreements9%
Bulk rHuPH208%
Sales-based milestone4%
Upfront Fees1%
By geography
Not disclosed.
The read
What is Halozyme Therapeutics, Inc.’s revenue?
Halozyme Therapeutics, Inc. booked $1.4B in FY2025 revenue, growing 38% year over year — faster than most Healthcare companies we track, at a 22.7% net margin.
Peers · Healthcare
LifeStance Health Group, Inc.65BAddus HomeCare Corporation80B+Penumbra, Inc.83B+CONMED Corporation83B+Haemonetics Corporation79B+HealthEquity, Inc.83B+Neighbors
San Diego →Key facts
CEOHelen I. Torley
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: HALO
Employees423
IPO date2004-03-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.